The Clinical Enigma of Cardiogenic Shock

Slides:



Advertisements
Similar presentations
The Nurse’s Role in Inflammatory Bowel Disease
Advertisements

Assist Devices for the Treatment of Cardiogenic Shock
Role of ECMO in Acute Cardiogenic Shock
circulatory support in cardiogenic shock
Silent No More:.
COPD by the Guidelines.
Exploring Early Combination Therapy in PAH
NOACs for Cancer-Associated Thrombosis:
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Making Decisions With Your Osteoarthritis Patients
NOACs In Long-term VTE Treatment: A State Of The Art Review
Acute Heart Failure.
The role of metabolic surgery in the management of obesity and t2dm
Cardiogenic Shock.
UNDERSTANDING RISK STRATIFICATION IN PAH:
Angiotensin as a Vasopressor in Vasodilatory Shock
Advances in Vasodilatory Shock:
Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update
Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.
Percutaneous Mechanical Circulatory Support Devices
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Decision-making in the eRA of Treating to Target
PAH Therapy Revisited.
Improving Risk Assessment and Early Diagnosis in PAH
Treating Vasodilatory Shock in the ICU
MDS: Introduction. Supportive Care in the Treatment of Lower-Risk Myelodysplastic Syndromes.
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Case Collection in RA: Highlights of an Interactive Workshop
Advances in the Management of Severe and Life-Threatening Chemotoxicity.
WHO Clinical Classification of PH Complex Cases in PH.
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited
Examining the Latest Evidence in PAH
Using Heart Rate as a Biomarker in Clinical Practice.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Physiology Myocardial Oxygen Supply and Demanda,b.
Aspirin and Cardioprevention in 2018
Oral Prostanoids and PAH
PAH Treatment.
Pulmonary Arterial Hypertension and Connective Tissue Disease
Managing HF in Primary Care
Oral Prostacyclin Pathway Agents in PAH
Pulmonary Hypertension Updates From 2018
PeaceHealth Southwest Hospital/Carson Tahoe Medical Center
Incorporating Prostacyclins Into Practice
The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.
Current Controversies and Advances in Hepatorenal Syndrome
Program Goals Background: Anticoagulation in Patients With VTE.
Perspective on the Multidisciplinary Management of PAH
A Multidisciplinary Perspective on the Management of Hypoparathyroidism.
Assessing the Burden of Hyperkalemia
Saving the Day.
Disease Burden of VTE Phases of VTE Treatment.
New Lipid-Lowering Guidelines
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Assessing the Burden of Hyperkalemia
Incorporating New PAH Treatments Into Clinical Practice
Rational Pharmacotherapy Selection for Insomnia
Evaluating Success of Current Treatments for HCM
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Evaluating the Science of Cardiogenic Shock
Importance of Early Diagnosis and Management in SMA
What's New in PAH?.
PCSK9 Inhibitors and Real-World Evidence
Understanding the Basics of Dementia-Related Psychosis
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

The Clinical Enigma of Cardiogenic Shock

Program Goals

Prevalence of Cardiogenic Shock

Clinical Scenario

Prompt Revascularization and Hemodynamic Support

Diagnosis and Classification

Signs and Symptoms of CS

CS Frequency, Trends, and Risk

Vasopressors vs Inotropes for Improvement in Organ Perfusion

SOAP II Trial – Norepinephrine vs Dopamine

Treatment Algorithm for Cardiogenic Shock

Potential CS Care Pathway

Device Selection

Types of pMCS Devices

Temporary pMCS vs Durable MCS

CS Center Characteristics

Reperfusion Strategy Selection

Delayed Implementation of Effective Therapies for Shock

The Role of Early RHC in CS Patients

Guideline Recommendations for Circulatory Support in Cardiogenic Shock

Prioritizing Lesion Revascularization

The Shock Team

Take Home Points

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)